Clinical Data ECO 2026: REDEFINE-1 demonstrates CagriSema’s improvement in body composition Pharmaceutical TechnologyData from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk's CagriSema in adults with obesity.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Turkiye, assessing Novo Nordisk’s CagriSema in adults with obesity. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switchingNext: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
